Daiichi Sankyo-Merck’s trial lung cancer drug meets primary goal
Daiichi Sankyo and Merck & Co., Inc. will initiate talks with global regulatory agencies after an end-stage trial of its drug for a.
Drugs
Health
Pharma
Drugs
Health
Pharma
Summit’s lung cancer drug reduces risk of disease progression by 48%
Summit Therapeutics Inc.’s investigational drug ivonescimab helps lung cancer patients to cut the risk of progression or death from the disease by 48%,.
Drugs
Health
Pharma
Illumina’s DNA sequencing cancer tests to check 500 genes get US nod
The US Federal Drug Administration approved Illumina Inc.’s DNA sequencing cancer tests that check more than 500 genes in a tumour to help.
Drugs
Health
Pharma
Denmark’s Pharmacosmos to buy G1 Therapeutics for $405 million
Danish biotechnology company, Pharmacosmos A/S will buy US-based G1 Therapeutics Inc., for $405 million to expand its global commercial portfolio in haematology.
Drugs
Health
Pharma
FDA rejects Daiichi, Merck, antibody-drug conjugate application
The USFDA has rejected a Biologics License Application from Daiichi Sankyo and Merck & Co., seeking accelerated approval of patritumab deruxtecan to treat.
Drugs
Health
Pharma
Pfizer’s drug helps people with rare lung cancer live longer, data shows
Sixty percent of the patients treated with Pfizer’s Lorbrena drug, for a rare form of advanced lung cancer, were alive without disease progression.
Drugs
Health
Pharma
AstraZeneca’s non-small lung cancer therapy gets FDA clearance
HQ Team February 17, 2024: The USFDA has cleared AstraZeneca’s Tagrisso with chemotherapy for treatment in adult patients with non-small cell lung cancer..
Drugs
Health
Pharma
FDA nod for Pfizer’s combination therapy for non-small cell cancer
HQ Team October 12, 2023: The Food and Drug Administration has approved Pfizer Inc.’s treatment for metastatic non-small cell lung cancer. The FDA.
